Efficacy and safety of alfaxalone compared to propofol in canine refractory status epilepticus: a pilot study

被引:0
|
作者
Al Kafaji, Tania [1 ]
Corda, Andrea [2 ]
Charalambous, Marios [3 ,4 ]
Murgia, Elsa [1 ]
Tartari, Ilaria [1 ]
Puci, Mariangela [5 ]
Debidda, Pasquale [1 ]
Gallucci, Antonella [1 ]
机构
[1] Vet Neurol Ctr La Fenice, Selargius, Italy
[2] Univ Sassari, Vet Teaching Hosp, Dept Vet Med, Sassari, Italy
[3] Blaise Vet Referral Hosp, Small Anim Clin, Birmingham, England
[4] Leibniz Univ Hannover, Dept Vet Med, Hannover, Germany
[5] Univ Sassari, Dept Med Surg & Pharm, Clin Epidemiol & Med Stat Unit, Sassari, Italy
关键词
status epilepticus; alfaxalone; propofol; dogs; seizures; NEUROACTIVE STEROIDS; TONIC INHIBITION; DOGS; MANAGEMENT; SEIZURES; INFUSION; RECEPTORS; CATS;
D O I
10.3389/fvets.2024.1383439
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Introduction Refractory status epilepticus (RSE) is defined as seizure activity that is minimally responsive to first- or second-line antiseizure medications. Constant rate infusion (CRI) intravenous propofol (PPF) is commonly used to treat RSE in dogs and cats. The antiseizure activity of alfaxalone (ALF) in RSE has been demonstrated in various experimental studies. This study compared the clinical efficacy and safety of intramuscular administration followed by CRI infusion of ALF with intravenous administration followed by CRI infusion of PPF to treat canine RSE.Materials and methods This was a multicenter, prospective, randomized clinical trial of client-owned dogs referred for status epilepticus that did not respond to first- and second-line drugs. Animals with suspected or confirmed idiopathic or structural epilepsy were included. The dogs were randomly assigned to either the PPF or ALF treatment groups and each group received drug CRI infusions for 6 h. Drug dosages were progressively reduced by 25% every hour from the third hour until suspension after 6 h. Patients were classified as responders or non-responders based on the relapse of epileptic seizures during the 24 h therapy infusion or within 24 h of drug suspension. Univariate statistical analyses were performed.Results Twenty dogs were enrolled in the study. Ten (10/20) dogs were randomly allocated to the PPF group and 10 (10/20) to the ALF group. Successful outcomes were obtained in six (6/10) patients in the PPF group and five (5/10) patients in the ALF group. Adverse effects were recorded in six (6/10) and three (3/10) animals in the PPF and ALF groups, respectively. No statistically significant differences in outcomes or the presence of adverse effects were observed between the groups.Discussion The results of this preliminary study suggest that ALF can be considered a valid and safe alternative to PPF for the treatment of RSE in dogs, with the additional advantage of intramuscular administration. However, caution should be exercised when using these drugs to provide airway and hemodynamic support.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] Intubation in propofol-treated status epilepticus: a cohort study
    Mikutra-Cencora, Maya
    Teitelbaum, Jeanne
    FRONTIERS IN MEDICINE, 2025, 12
  • [42] Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: A systematic review
    Claassen, J
    Hirsch, LJ
    Emerson, RG
    Mayer, SA
    EPILEPSIA, 2002, 43 (02) : 146 - 153
  • [43] Comparative efficacy and safety of second-line medications for status epilepticus A network meta-analysis
    Zhang, Qishun
    Peng, Shaokang
    Wei, Ziyi
    Cheng, Xiangshu
    MEDICINE, 2024, 103 (46) : e40333
  • [44] Efficacy and safety of ketamine for pediatric and adolescent super-refractory status epilepticus and the effect of cerebral inflammatory conditions
    Kuki, Ichiro
    Inoue, Takeshi
    Fukuoka, Masataka
    Nukui, Megumi
    Okuno, Hideo
    Amo, Kiyoko
    Otsuka, Yasunori
    Ishikawa, Junichi
    Rinka, Hiroshi
    Ujiro, Atushi
    Togawa, Masao
    Shiomi, Masashi
    Okazaki, Shin
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2024, 459
  • [45] Efficacy of intravenous lacosamide as an add-on treatment in refractory status epilepticus: A multicentric prospective study
    Miro, J.
    Toledo, M.
    Santamarina, E.
    Ricciardi, A. C.
    Villanueva, V.
    Pato, A.
    Ruiz, J.
    Juvany, R.
    Falip, M.
    SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2013, 22 (01): : 77 - 79
  • [46] Refractory and super-refractory status epilepticus in children and adolescents: A population-based study
    Hepo, Seline W.
    Lee, Maya
    Noszka, Kristoffer
    Wollertsen, Yvonne Myrtvedt
    Holmaas, Gunhild
    Kristensen, Erle
    Eichele, Tom
    Bjork, Marte-Helene
    Griffiths, Silja T.
    Hikmat, Omar
    SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2024, 120 : 116 - 123
  • [47] A Comparative Study of Midazolam and Target-Controlled Propofol Infusion in the Treatment of Refractory Status Epilepticus
    Masapu, Dheeraj
    Krishna, K. N. Gopala
    Sanjib, Sinha
    Chakrabarti, Dhrithiman
    Mundlamuri, R. C.
    Manohar, Nitin
    Mariamma, P.
    Satishchandra, P.
    Rao, G. S. Umamaheswara
    INDIAN JOURNAL OF CRITICAL CARE MEDICINE, 2018, 22 (06) : 441 - 448
  • [48] Propofol Infusion Syndrome During Refractory Status Epilepticus in a Young Adult: Successful ECMO Resuscitation
    Christophe Guitton
    Laurence Gabillet
    Patrick Latour
    Jean-Christophe Rigal
    David Boutoille
    Ousama Al Habash
    Pascal Derkinderen
    Cédric Bretonniere
    Daniel Villers
    Neurocritical Care, 2011, 15 : 139 - 145
  • [49] Early EEG Monitoring for Detecting Postanoxic Status Epilepticus during Therapeutic Hypothermia: A Pilot Study
    Legriel, Stephane
    Bruneel, Fabrice
    Sediri, Haouaria
    Hilly, Julia
    Abbosh, Nathalie
    Lagarrigue, Matthieu Henry
    Troche, Gilles
    Guezennec, Pierre
    Pico, Fernando
    Bedos, Jean Pierre
    NEUROCRITICAL CARE, 2009, 11 (03) : 338 - 344
  • [50] Efficacy of lacosamide in neonatal-onset super-refractory status epilepticus: a case report
    Bertozzi, Veronica
    Bonardi, Claudia M.
    Biscalchin, Gaia
    Tona, Clarissa
    Amigoni, Angela
    Sartori, Stefano
    EPILEPTIC DISORDERS, 2021, 23 (04) : 655 - 660